ClinicalTrials.gg
Sign In

Drug

Anti-HER2 Antibody-drug Conjugate BL-M07D1 clinical trials

studies test it
21
open now
17
in phase 3
11
first study started
2022

Keep track of what changes. Save the Anti-HER2 Antibody-drug Conjugate BL-M07D1 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

BL-M07D1
21

Studies by the year they started

21 studies that test it; most in 2024 (7)

Studies that test Anti-HER2 Antibody-drug Conjugate BL-M07D1, by start year
YearStudies
20221
20231
20247
20255
20267

By phase

A phase 1/2 study counts in both.

Phase 1
6
Phase 2
8
Phase 3
11

What it is tested for

Each study’s main condition, where its own words name it.

Breast Neoplasms
2
Carcinoma, Non-Small-Cell Lung
1
Colorectal Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Endometrial Neoplasms
1
Urinary Bladder Neoplasms
1
Biliary Tract Neoplasms
1

Who runs them

Industry 21 · Other 0

Sichuan Baili Pharmaceutical Co., Ltd. (19) · SystImmune Inc. (2)

Often tested with

Tested in the same studies.

Pertuzumab (1) · Docetaxel (1) · Ado-Trastuzumab Emtansine (1) · Pembrolizumab (1)

Studies

Open first, then newest update. How each study uses Anti-HER2 Antibody-drug Conjugate BL-M07D1 is read from its arms, and is right about nine times in ten.

Testing it · 21

See all 21 studies that test Anti-HER2 Antibody-drug Conjugate BL-M07D1 →